Smith & Nephew targets strong growth and launches $500M buyback amid share price dip

Smith & Nephew, a UK-based medical device maker, reports solid recovery with revenue, profit, and cash flow growth across divisions. The company aims for 6% revenue growth, 8% organic profit growth, and $800 million free cash flow by 2026, supported by a new $500 million share buyback. Despite missing some margin targets, a new strategy called 'RISE' sets financial goals for 2028. After an 18% share price drop, valuation metrics now appear attractive to investors.